Lipella pharmaceuticals reports encouraging early tolerability results in phase 2a trial of lp-310 for oral lichen planus

Pittsburgh, sept. 24, 2024 – prism mediawire – lipella pharmaceuticals inc. (nasdaq: lipo) (“lipella” or the “company”), a clinical-stage biotechnology company focused on addressing serious diseases with significant unmet needs, today announced an update on its ongoing multi-center phase 2a clinical trial evaluating lp-310 for the treatment of oral lichen planus (olp).
LIPO Ratings Summary
LIPO Quant Ranking